Clinical Studies

  • In a single‑center, consecutive series study (50 patients) on the use of a novel platelet‑rich fibrin matrix (PRFM) and beta‑tricalcium phosphate, Cammisa et. al, showed a 92.4% fusion rate at 12 months using CT scans without complications, infections, or revisions. Significant improvement in VAS scores for both back and leg pain (p<0.05) and the number of patients using opioid analgesics at 12-months decreased by 38% in posterolateral lumbar fusion.6
  • In a randomized, controlled trial, Barber et. al, used the platelet‑rich fibrin membrane (PRFM) to augment rotator cuff repair surgery by comparing a triple-loaded, single-row repair (two fixation anchors) with PRFM vs. a double-row repair (4 anchors).  Both repairs showed excellent results however, the PRFM group used two fewer anchors.7
  • A novel autologous platelet-rich fibrin membrane (PRFM) was used to facilitate healing in patients with unresponsive lower-extremity wounds. All patients enrolled in the study had failed conventional treatment, received up to three applications of the PRFM (35 to 50 mm fibrin disc), and were assessed using standard methods. Sixty-seven percent (67%) of the patients healed with an average of two applications in under 8 weeks.8